The effects of pharmacological opioid blockade on neural measures of drug cue-reactivity in humans

Neuropsychopharmacology

Volumn 41, Issue 12, 2016, Pages 2872-2881

  Courtney, Kelly E ^a   Ghahremani, Dara G ^a   Ray, Lara A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE; NALTREXONE; PLACEBO; CENTRAL STIMULANT AGENT; NARCOTIC ANTAGONIST; OXYGEN;

ADULT; ALCOHOL ABSTINENCE; ARTERIAL SPIN LABELING; ARTICLE; BOLD SIGNAL; CLINICAL ARTICLE; CONTROLLED STUDY; DORSAL STRIATUM; DRUG CRAVING; DRUG EFFECT; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; INFERIOR FRONTAL GYRUS; MALE; METHAMPHETAMINE DEPENDENCE; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE SCANNER; PARIETAL LOBE; PRECUNEUS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SUPERIOR FRONTAL GYRUS; THALAMUS; VENTRAL STRIATUM; VENTRAL TEGMENTUM; ASSOCIATION; BEHAVIOR, ADDICTIVE; BLOOD; BRAIN; BRAIN MAPPING; DIAGNOSTIC IMAGING; DRUG EFFECTS; FEMALE; IMAGE PROCESSING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE-RELATED DISORDERS;

ADULT; BEHAVIOR, ADDICTIVE; BRAIN; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM STIMULANTS; CUES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; METHAMPHETAMINE; NALTREXONE; NARCOTIC ANTAGONISTS; OXYGEN; SUBSTANCE-RELATED DISORDERS;

EID: 84978121095     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.99     Document Type: Article

References (54)

1. Anggadiredja K, Sakimura K, Hiranita T, Yamamoto T (2004). Naltrexone attenuates cue- but not drug-induced methamphet-amine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res 1021: 272-276.
2. Beck A, Wustenberg T, Genauck A, Wrase J, Schlagenhauf F, Smolka MN et al (2012). Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. Arch Gen Psychiatry 69: 842-852.
3. Benjamin D, Grant ER, Pohorecky LA (1993). Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 621: 137-140.
4. Berman S, O'Neill J, Fears S, Bartzokis G, London ED (2008). Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci 1141: 195-220.
5. Berridge KC, Robinson TE (2003). Parsing reward. Trends Neurosci 26: 507-513.
6. Boettiger CA, Kelley EA, Mitchell JM, D'Esposito M, Fields HL (2009). Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav 93: 291-299.
7. Carr DB, Sesack SR (2000). GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. Synapse 38: 114-123.
8. Catafau AM, Etcheberrigaray A, Perez de los Cobos J, Estorch M, Guardia J, Flotats A et al (1999). Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification. J Nucl Med 40: 19-24.
9. Cavanna AE, Trimble MR (2006). The precuneus: a review of its functional anatomy and behavioural correlates. Brain 129(Part 3): 564-583.
10. Courtney KE, Ghahremani DG, London ED, Ray LA (2014a). The association between cue-reactivity in the precuneus and level of dependence on nicotine and alcohol. Drug Alcohol Depend 141: 21-26.
11. Courtney KE, Ghahremani DG, Ray LA (2013). Fronto-striatal functional connectivity during response inhibition in alcohol dependence. Addict Biol 18: 593-604.
12. Courtney KE, Ray LA (2014b). Subjective responses to alcohol in the lab predict neural responses to alcohol cues. J Stud Alcohol Drugs 75: 124-135.
13. Courtney KE, Schacht JP, Hutchison K, Roche DJO, Ray LA (2016). Neural substrates of cue-reactivity: association with treatment outcomes and relapse. Addict Biol 21: 3-22.
14. De Wit H (1996). Priming effects with drugs and other reinforcers. Exp Clin Psychopharmacol 4: 5-10.
15. Delgado MR, Stenger VA, Fiez JA (2004). Motivation-dependent responses in the human caudate nucleus. Cereb Cortex 14: 1022-1030.
16. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994). Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271: 1630-1637.
17. Engelmann JM, Versace F, Robinson JD, Minnix JA, Lam CY, Cui Y et al (2012). Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies. Neuroimage 60: 252-262.
18. Everitt BJ, Robbins TW (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8: 1481-1489.
19. Feil J, Sheppard D, Fitzgerald PB, Yucel M, Lubman DI, Bradshaw JL (2010). Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Neurosci Biobehav Rev 35: 248-275.
20. Goldstein RZ, Volkow ND (2011). Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12: 652-669.
21. Haber SN, Kim K-S, Mailly P, Calzavara R (2006). Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. J Neurosci 26: 8368-8376.
22. Hare TA, Camerer CF, Rangel A (2009). Self-control in decision-making involves modulation of the vmPFC valuation system. Science 324: 646-648.
23. Heatherton TF, Wagner DD (2011). Cognitive neuroscience of self-regulation failure. Trends Cogn Sci 15: 132-139.
24. Itzhak Y, Ali SF (2002). Behavioral consequences of metham-phetamine-induced neurotoxicity in mice: relevance to the psychopathology of methamphetamine addiction. Ann N Y Acad Sci 965: 127-135.
25. Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J (2008). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165: 1442-1448.
26. Kalivas PW, Volkow ND (2005). The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162: 1403-1413.
27. Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R et al (2006). Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology 31: 644-650.
28. Lee YK, Park SW, Kim YK, Kim DJ, Jeong J, Myrick H et al (2005). Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol 40: 297-301.
29. Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J et al (2013). Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Neuroimage 78: 176-185.
30. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL (2006). Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A 103: 2938-2942.
31. Miranda R, Ray L, Blanchard A, Reynolds EK, Monti PM, Chun T et al (2014). Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addict Biol 19: 941-954.
32. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM et al (1999). Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23: 1386-1394.
33. Murty VP, Shermohammed M, Smith DV, Carter RM, Huettel SA, Adcock RA (2014). Resting state networks distinguish human ventral tegmental area from substantia nigra. Neuroimage 100: 580-589.
34. O'Reilly JX, Woolrich MW, Behrens TE, Smith SM, Johansen-Berg H (2012). Tools of the trade: psychophysiological interactions and functional connectivity. Soc Cogn Affect Neurosci 7: 604-609.
35. Preston KL, Bigelow GE (1993). Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264: 813-823.
36. Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D et al (2015a). The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology 40: 2347-2356.
37. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED (2015b). Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alcohol Abuse 41: 35-44.
38. Ray LA, Courtney KE, Roche D, Miotto K (in press). Application of functional neuroimaging to the treatment of addiction: focus on pharmacotherapies. In: Filbey F, Feldstein-Ewing SW, Witkiewitz K (eds). Neuroimaging and Psychosocial Addiction Treatment: sAn Integrative Guide for Researchers and Clinicians. Palgrave: New York, NY.
39. Ray LA, Hutchison KE (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64: 1069-1077.
40. Ray LA, Hutchison KE, MacKillop J, Miranda R Jr, Audette A, Swift R et al (2008). Effects of naltrexone during the descending limb of the blood alcohol curve. Am J Addict 17: 257-264.
41. Robinson TE, Berridge KC (2001). Incentive-sensitization and addiction. Addiction 96: 103-114.
42. Schacht JP, Anton RF, Myrick H (2013a). Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol 18: 121-133.
43. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H (2013b). Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl) 227: 627-637.
44. Schuh KJ, Walsh SL, Stitzer ML (1999). Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 145: 162-174.
45. Seger CA (2013). The visual corticostriatal loop through the tail of the caudate: circuitry and function. Front Syst Neurosci 7: 104.
46. Sinha R (2013). The clinical neurobiology of drug craving. Curr Opin Neurobiol 23: 649-654.
47. Syed YY, Keating GM (2013). Extended-release intramuscular naltrexone (VIVITROL(R)): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs 27: 851-861.
48. Tien LT, Ho IK, Loh HH, Ma T (2007). Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice. J Neurosci Res 85: 673-680.
49. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L et al (1998). Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466.
50. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR et al (2006). Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26: 6583-6588.
51. Vollstadt-Klein S, Wichert S, Rabinstein J, Buhler M, Klein O, Ende G et al (2010). Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction 105: 1741-1749.
52. Wang DJ, Chen Y, Fernandez-Seara MA, Detre JA (2011). Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 337: 359-366.
53. Worsley KJ (2001). Statistical analysis of activation images. In: Jezzard P, Matthews PM, Smith SM (eds). Functional MRI: An Introduction to Methods. Oxford University Press: New York, NY.
54. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ (1996). Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2: 1225-1229.